Filing Details
- Accession Number:
- 0001209191-20-010537
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-19 16:32:41
- Reporting Period:
- 2020-02-17
- Accepted Time:
- 2020-02-19 16:32:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-17 | 2,496 | $241.50 | 44,839 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-18 | 760 | $242.08 | 44,079 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 1,011 | $242.91 | 43,068 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 400 | $243.76 | 42,668 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 580 | $245.04 | 42,088 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 377 | $245.76 | 41,711 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $242.91 (range $242.43 to $243.42).
- Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.45 to $244.43).
- Open market sales reported on this line occurred at a weighted average price of $245.04 (range $244.52 to $245.44).
- Open market sales reported on this line occurred at a weighted average price of $245.76 (range $245.54 to $245.90).
Billionaire Hedge Funds
